Two New Antiseizure Drugs: A Pharmacist Perspective

Published Online: Tuesday, March 20, 2012
Follow Pharmacy_Times:
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Barry Gidal, PharmD, professor of pharmacy and neurology at the University of Wisconsin, about two new antiepileptic drugs (AEDs): ezogabine and perampanel.
 
Dr. Gidal explains that ezogabine, which was approved by the FDA in June 2011, helps to reduce seizure activity by keeping the potassium channels of neurons open, while perampanel, which has not yet been approved, blocks the stimulation of 1 of 3 key neuronal receptors that are thought to be key in starting and continuing seizures. He explains that both medications have shown very good promise in reducing seizure activity in patients who have failed to respond to multiple other AEDs and do not appear to have serious side effects or drug interaction problems.
 
To listen to the podcast, click here and scroll down to the October 28, 2011, episode.
Related Articles
Researchers at the American Epilepsy Society meeting reported important strides in the understanding of epilepsy, including identification of new therapeutic targets in the brain, as discussed by Esther Krook-Magnuson, PhD, as well as improved understanding of the factors involved in sudden death of patients with epilepsy, and a greater recognition of the benefits of neurosurgery in patients with epilepsy.
Several new antiepileptic drugs have recently been approved in the United States. In a symposium at the American Epilepsy Society in Seattle, Washington, Professor Martin J. Brodie, MD, director of the epilepsy unit of the Western Infirmary in Glasgow, Scotland, discussed some considerations with ezogabine and eslicarbazepine.
Mark Cook, MD, of the University of Melbourne, and Brian Litt, MD, of the Penn Epilepsy Center and the Center for Neuroengineering and Therapeutics at the University of Pennsylvania, discuss how new devices, big data, and massive online competitions are enabling prediction of seizures before they start.
S. L. Moshé, MD, of the Albert Einstein College of Medicine and Montefiore Medical Center, discusses the importance of creating disease-specific models of epilepsy in animal models for understanding and treating specific epilepsy subtypes.
Latest Issues
$auto_registration$